SIGN UP
LOG IN
A
09926
Akeso
116.10
10.00+9.43%Closed16:08 07/04 HKT
OPEN/PREV CLOSE110.500/106.100
TODAY RANGE109.900-116.500
VOL30.95M
MARKET CAP104.21B
52 WEEK RANGE35.750-116.500
AVG VOL (3M)15.33M
% TURNOVER3.45%
TURNOVER3.50B
P/E (TTM)-187.561
% RANGE6.22%
EPS(TTM)-0.619
P/E(FORWARD)2,491.416
P/B14.163
BVPS8.198
DIVIDEND--
P/S45.435
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP104.21B
SHARES OUTSTANDING897.59M
NEXT EARNINGS08/26-09/02
FREE FLOAT897.59M
LOT SIZE1000
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·10h ago
What Akeso, Inc.'s (HKG:9926) 31% Share Price Gain Is Not Telling You
Simply Wall St·06/23 22:20
Here's Why Akeso, Inc.'s (HKG:9926) CEO May Deserve A Raise
Simply Wall St·06/17 04:07
Asian Stocks That Might Be Trading Below Estimated Value
Simply Wall St·06/15 00:12
Institutions profited after Akeso, Inc.'s (HKG:9926) market cap rose HK$12b last week but individual investors profited the most
Reuters·06/11 10:53
BUZZ-Summit slips as Leerink doubts cancer drug can match Keytruda's success
Barron‘s·05/20 14:46
Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid.
Simply Wall St·05/07 23:33
Akeso, Inc.'s (HKG:9926) Shares Climb 29% But Its Business Is Yet to Catch Up
Simply Wall St·05/03 01:32
Earnings Update: Here's Why Analysts Just Lifted Their Akeso, Inc. (HKG:9926) Price Target To HK$104
Simply Wall St·05/02 01:29
Akeso Full Year 2024 Earnings: Misses Expectations
Simply Wall St·04/28 04:08
Exploring High Growth Tech Stocks in Asia April 2025
Reuters·04/25 22:01
BUZZ-Summit Therapeutics closes 36% lower after interim data for cancer drug
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.